Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Taysha Gene Therapies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMMENCED SITE ACTIVATION FOR REVEAL PIVOTAL TRIAL IN ACCORDANCE WITH PREVIOUSLY ALIGNED UPON KEY DESIGN ELEMENTS, FOLLOWING RECEIPT OF NO OBJECTION LETTER (NOL) FROM HEALTH CANADA AND FEEDBACK FROM THE FDA; PATIENT ENROLLMENT ANTICIPATED TO BEGIN IN Q4 2025

TAYSHA GENE THERAPIES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

DALLAS, AUG. 05, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC.(NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND HOST A CORPORATE UPDATE CONFERENCE CALL AND WEBCAST ON TUESDAY, AUGUST 12, 2025, AT 8:30 AM EASTERN TIME.

TAYSHA GENE THERAPIES TO RELEASE SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON AUGUST 12

DALLAS, AUG. 01, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON AUGUST 1, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED ONE NEW EMPLOYEE AN OPTION TO PURCHASE 90,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTION WAS GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUAL ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

TAYSHA GENE THERAPIES ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

DALLAS, JULY 03, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON JULY 1, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED TWO NEW EMPLOYEES, IN THE AGGREGATE, OPTIONS TO PURCHASE 30,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTIONS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

DALLAS, JUNE 06, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON JUNE 2, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED TWO NEW EMPLOYEES, IN THE AGGREGATE, OPTIONS TO PURCHASE 401,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTIONS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

RECENTLY DISCLOSED CLINICAL COHORT DATA FROM HIGH (1X10 15 TOTAL VG) AND LOW DOSE (5.7X10 14 TOTAL VG) TSHA-102 FROM REVEAL ADOLESCENT/ADULT AND PEDIATRIC PHASE 1/2 TRIALS

TAYSHA GENE THERAPIES ANNOUNCES DETAILS FOR ORAL PRESENTATIONS AT THE 2025 IRSF RETT SYNDROME SCIENTIFIC MEETING REVIEWING RECENT UPDATES FROM THE TSHA-102 CLINICAL PROGRAM

DALLAS, MAY 28, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 46,868,687 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $2.75 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE 25,858,586 SHARES OF ITS COMMON STOCK AT AN OFFERING PRICE OF $2.749 PER PRE-FUNDED WARRANT, IN EACH CASE BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SECURITIES ARE BEING OFFERED BY TAYSHA. IN ADDITION, TAYSHA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 10,909,090 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS FROM THE OFFERING TO TAYSHA ARE EXPECTED TO BE APPROXIMATELY $200.0 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT MAY 30, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

TAYSHA GENE THERAPIES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

DALLAS, MAY 28, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. ALL OF THE SECURITIES WILL BE OFFERED BY TAYSHA. TAYSHA ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK OFFERED IN THE PUBLIC OFFERING UNDER THE SAME TERMS AND CONDITIONS (INCLUDING SHARES UNDERLYING THE PRE-FUNDED WARRANTS). THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR THE ACTUAL SIZE OR TERMS OF THE OFFERING.

TAYSHA GENE THERAPIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

NATURAL HISTORY DATA ANALYSIS ESTABLISHED PATIENTS  SIX YEARS OF AGE ARE IN DEVELOPMENTAL PLATEAU, WITH A ~0% LIKELIHOOD OF GAINING/REGAINING DEVELOPMENTAL MILESTONES ACROSS THE CORE FUNCTIONAL DOMAINS OF RETT SYNDROME

TAYSHA GENE THERAPIES ANNOUNCES PIVOTAL PART B TRIAL DESIGN DETAILS FOR TSHA-102 IN RETT SYNDROME ENABLED BY IRSF NATURAL HISTORY DATA AND POSITIVE CLINICAL DATA FROM PART A OF THE REVEAL ADULT/ADOLESCENT AND PEDIATRIC TRIALS EVALUATING TSHA-102

OBTAINED WRITTEN ALIGNMENT FROM THE FDA ON KEY ELEMENTS OF TSHA-102 PIVOTAL PART B TRIAL DESIGN AND NEXT STEPS ON ENABLING STUDY INITIATION THE FDA ADVISED THE COMPANY TO SUBMIT PIVOTAL PART B TRIAL PROTOCOL AND ASSOCIATED STATISTICAL ANALYSIS PLAN AS AN AMENDMENT TO THE IND APPLICATION, ELIMINATING THE NEED FOR FORMAL END-OF-PHASE MEETING AND POTENTIALLY EXPEDITING STUDY INITIATION AND REGISTRATION; IND AMENDMENT SUBMISSION EXPECTED IN Q2 2025 HIGH DOSE AND LOW DOSE OF TSHA-102 CONTINUE TO BE GENERALLY WELL TOLERATED WITH NO TREATMENT-RELATED SAES OR DLTS IN THE PEDIATRIC, ADOLESCENT AND ADULT PATIENTS TREATED (HIGH DOSE, N=6; LOW DOSE, N=4) ACROSS BOTH REVEAL TRIALS AS OF APRIL 10, 2025, DATA CUTOFF PROGRAM UPDATE ON PIVOTAL TRIAL DESIGN, RETT SYNDROME NATURAL HISTORY DATA ANALYSIS AND CLINICAL DATA FROM COHORT TWO (HIGH DOSE) AND COHORT ONE (LOW DOSE) OF BOTH REVEAL TRIALS EXPECTED IN Q2 2025 IN CONJUNCTION WITH IRSF RETT SYNDROME SCIENTIFIC MEETING  CONFERENCE CALL AND LIVE WEBCAST TODAY AT8:30 AM EASTERN TIME DALLAS, MAY 15, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDEDMARCH 31, 2025, AND PROVIDED A CORPORATE UPDATE. WE ARE PLEASED WITH THE SIGNIFICANT REGULATORY AND CLINICAL PROGRESS ACROSS OUR TSHA-102 PROGRAM IN CLINICAL EVALUATION FOR CHILDREN, ADOLESCENTS AND ADULTS SUFFERING FROM RETT SYNDROME.

TAYSHA GENE THERAPIES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

DALLAS, MAY 08, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND HOST A CORPORATE UPDATE CONFERENCE CALL AND WEBCAST ON THURSDAY, MAY 15, 2025, AT 8:30 AM EASTERN TIME.

Taysha Gene Therapies, Inc.

TSHA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Taysha Gene Therapies, Inc.

TSHA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TSHA